BOCA RATON, Fla., Oct. 10 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) will announce third quarter 2006
financial results on Wednesday, October 25, 2006, after market close. The
company will host a conference call and live webcast at 4:30 p.m. ET.
The live webcast can be accessed at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=100445&eventID=1399547 or via the Nabi Biopharmaceuticals
website at http://www.nabi.com. If you do not have Internet access, the
U.S./Canada call-in number is 866-277-1182 conference code 73651534, and the
international call-in number is 617-597-5359 conference code 73651534. An
audio replay will be available for U.S./Canada callers at 888-286-8010
conference code 57282531, and for international callers at 617-801-6888
conference code 57282531.
An archived version of the webcast will be available at the same
Internet address through November 1, 2006. The audio replay will also be
available through November 1, 2006. The press release will be available on
the company's website at http://www.nabi.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has three products on the market
today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin
(Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi
Biopharmaceuticals is focused on developing products that address unmet
medical needs and offer commercial opportunities in our core business
areas: hepatitis and transplant, kidney disease (nephrology), Gram-positive
bacterial infections and nicotine addiction. For a complete list of
pipeline products, please go to: http://www.nabi.com/pipeline/index.php.
The company is headquartered in Boca Raton, Florida. For additional
information about Nabi Biopharmaceuticals, please visit our website:
http://www.nabi.com.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php
CONTACT:
Thomas E. Rathjen, Vice President, Investor
Relations of Nabi Biopharmaceuticals, +1-561-989-5800
|
